...
首页> 外文期刊>Pediatric Research >Fetal Fatty Acid Oxidation Disorders, Their Effect on Maternal Health and Neonatal Outcome: Impact of Expanded Newborn Screening on Their Diagnosis and Management
【24h】

Fetal Fatty Acid Oxidation Disorders, Their Effect on Maternal Health and Neonatal Outcome: Impact of Expanded Newborn Screening on Their Diagnosis and Management

机译:胎儿脂肪酸氧化紊乱及其对孕产妇健康和新生儿结局的影响:扩大新生儿筛查对其诊断和治疗的影响

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Mitochondrial fatty acid oxidation disorders (FAOD) are recessively inherited errors of metabolism. Newborns with FAOD typically present with hypoketotic hypoglycemia, metabolic acidosis, hepatic failure, and cardiomyopathy. Late presentations include episodic myopathy, neuropathy, retinopathy, and arrhythmias. Sudden unexpected death can occur at any age and can be confused with sudden infant death syndrome. Some FAOD are associated with intrauterine growth restriction, prematurity, and pregnancy complications in the heterozygous mother, such as severe preeclampsia, acute fatty liver of pregnancy (AFLP), or hemolysis, elevated liver enzymes, and low platelets (HELLP) syndrome. Maternal pregnancy complications occur primarily in mothers carrying a fetus with long-chain l-3-hydroxyacyl CoA dehydrogenase deficiency or general trifunctional protein deficiencies. FAOD as a group represent the most common inborn errors of metabolism, and presymptomatic diagnosis of FAOD is the key to reduce morbidity and avoid mortality. The application of tandem mass spectrometry to newborn screening provides an effective means to identify most FAOD patients presymptomatically. At the beginning of 2005, 36 state newborn screening programs have mandated or adopted this technology resulting in a marked increase in the number of asymptomatic neonates with FAOD diagnosed. To ensure the long-term benefits of such screening programs, pediatricians and other health care providers must be educated about these disorders and their treatment.Abbreviations: AFLP, acute fatty liver of pregnancy; FAO, fatty acid oxidation; FAOD, fatty acid oxidation disorders; HELLP, hemolysis, elevated liver enzymes, and low platelets syndrome; HMGCL, 3-hydroxy-3-methylglutaryl-CoA lyase; HMGCS2, 3-hydroxy-3-methylglutaryl-CoA synthetase; LCAD, long-chain acyl CoA dehydrogenase; LCHAD, long-chain l-3-hydroxyacyl CoA dehydrogenase; LKAT, long-chain 3-ketoacyl-CoA thiolase; MCAD, medium-chain acyl CoA dehydrogenase; MS/MS, tandem mass spectrometry; MTP, mitochondrial trifunctional protein; OA, organic acidemias; SCHAD, short-chain l-3-hydroxyacyl CoA dehydrogenase; SIDS, sudden infant death syndrome; VLCAD, very-long-chain acyl CoA dehydrogenase
机译:线粒体脂肪酸氧化失调(FAOD)是隐性遗传的代谢错误。患有FAOD的新生儿通常表现为低酮症性低血糖,代谢性酸中毒,肝功能衰竭和心肌病。晚期表现包括发作性肌病,神经病,视网膜病和心律不齐。突然的意外死亡可能发生在任何年龄,并可能与婴儿猝死综合症相混淆。某些FAOD与杂合子母亲的宫内生长受限,早产和妊娠并发症有关,例如严重的先兆子痫,妊娠急性脂肪肝(AFLP)或溶血,肝酶升高和低血小板(HELLP)综合征。产妇妊娠并发症主要发生在携带长链1-3-羟酰基辅酶A脱氢酶缺乏症或一般三功能蛋白缺乏症的母亲中。作为一个整体,FAOD代表了最常见的先天性代谢错误,对FAOD的症状前诊断是降低发病率和避免死亡率的关键。串联质谱在新生儿筛查中的应用提供了一种有效的手段,可以在症状发生前识别出大多数FAOD患者。 2005年初,已有36个州的新生儿筛查计划强制或采用了这项技术,导致诊断为FAOD的无症状新生儿数量明显增加。为了确保此类筛查计划的长期利益,必须教育儿科医生和其他医疗保健提供者有关这些疾病及其治疗的知识。粮农组织,脂肪酸氧化; FAOD,脂肪酸氧化失调; HELLP,溶血,肝酶升高和低血小板综合征; HMGCL,3-羟基-3-甲基戊二酰辅酶A裂解酶; HMGCS2,3-羟基-3-甲基戊二酰辅酶A合成酶; LCAD,长链酰基辅酶A脱氢酶; LCHAD,长链1-3-羟基酰基辅酶A脱氢酶; LKAT,长链3-酮酰基-CoA硫解酶; MCAD,中链酰基辅酶A脱氢酶; MS / MS,串联质谱; MTP,线粒体三功能蛋白; OA,有机酸血症; SCHAD,短链1-3-羟基酰基辅酶A脱氢酶;小岛屿发展中国家,婴儿猝死综合症; VLCAD,超长链酰基辅酶A脱氢酶

著录项

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号